DaVita Clinical Research Celebrates Milestone Year

  DaVita Clinical Research Celebrates Milestone Year

    2012 Brought New Jobs, Innovative Clinical Research Programs and More

Business Wire

DENVER -- December 27, 2012

DaVita Clinical Research^® (DCR^®), a provider of clinical research services
focused on kidney research as well as a multitude of specialty therapeutic
populations, today released a recap of its milestone year in 2012.

“DaVita Clinical Research experienced a very strong year in 2012,” said Dr.
Mahesh Krishnan, vice president of DaVita Clinical Research. “From expanding
our research capabilities to producing innovative studies with results to
drive better clinical outcomes, we’re making strides to improve the quality of
life for chronic kidney disease and end-stage renal disease patients around
the world.”

Major initiatives and highlights for DCR in 2012 include:

New research facility opened in Colorado – The new facility encompasses 35,000
square feet and is physically connected to St. Anthony Hospital in Lakewood,
Colo. The 80-bed facility brought more than 50 specialized research jobs to
the area and increased DCR’s physical capacity from 42 to 122 beds in North
America, including the existing facility in Minnesota. The facility supports
high-risk studies and has expanded ability to support both patient and healthy
volunteer Phase I clinical studies.

DCR hired four key individuals to ignite the expansion at its latest clinical
research facility. The new team members are Dr. Christopher Galloway, medical
director; Chad Jaeger, vice president of Clinical Operations; Amy Denvir,
director of Operations - Denver; and Michael Kreuter, director of Data
Management.

Through this investment, DCR will continue to explore opportunities to both
expand its patient-driven leadership position and diversify its ability to
conduct critical research in healthy normal volunteers.

Innovative clinical research programs highlighted at industry meetings –
Researchers from DCR and DaVita®, the dialysis division of DaVita HealthCare
Partners Inc., presented results from a number of innovative clinical
improvement programs and health economic studies originating from DaVita and
its research partners. The findings were shared at three premier health care
meetings in 2012: The National Kidney Foundation Spring Clinical Meeting, the
17^th Annual International Society for Pharmacoeconomics and Outcomes Research
International Meeting, and the American Society of Nephrology’s Kidney Week.

DCR provides a collaborative bridge between DaVita services and the
pharmaceutical and biotech research community; DCR also shares DaVita’s
dedication to improving the health and well-being of kidney patients.

2012 abstract highlights include the following:

  *Video Education Increases Patient Knowledge about Phosphorus Control and
    is a Preferred Form of Education (Duane Dunn, et al.)
  *Improvement in Peritonitis Rates with the Use of Sodium Hypochlorite (Dr.
    John Moran, et al.)
  *Disease Management Program Reduces Overall Medical Costs in End-Stage
    Renal Disease Patients (Dr. Allen R. Nissenson, et al.)
  *Results of a One-Year Assessment of Quality Indicators in an Acute
    Dialysis Program Operated by a Large Dialysis Provide (Dr. Robert
    Provenzano, et al.)
  *Crit-Line Monitor Use in Incident Hemodialysis Patients Improves Dry
    Weight and Adequacy, While Reducing Epoetin Alfa Dose: A Propensity Score
    Matched Study (Scott Sibbel, PhD et al.)
  *Extracellular Volume Control in Dialysis Patients To Reduce
    Hospitalizations (joint study between DaVita, Fresenius Medical Care, and
    Renal Ventures, LLL; presented by Thomas Parker, M.D., Renal Ventures
    Management, LLC)
  *Analysis of the 2014 Quality Improvement Program Reporting Measures for
    Calcium Phosphate in Dialysis Patients (Nissenson, et al.)
  *Changing Hemoglobin Targets: Effects on Epoetin Alfa, Intravenous Iron,
    and Iron Storage Measures From 2009–2012 (Bond, et al.)
  *A Comparative Analysis of Transfusion Trends between Types of Providers of
    Dialysis Services Using Medicare Claims Data (Krishnan, et al.)
  *Pseudo-Randomization in Retrospective Analysis Using the Generalized
    Multinomial Logit for Propensity Score Generation
  *Odds of Missed Hemodialysis Sessions are Increased During Holiday Periods
    Among In-Center Hemodialysis Patients
  *A Managed Care Cost-Offset Model for Ferric Citrate, an Experimental
    Phosphate Binder that Can Reduce the Use of Erythropoiesis-Stimulating
    Agents (ESA) and Intravenous Iron in Hemodialysis Patients with
    Hyperphosphatemia

Enhanced social media presence – In 2012 DCR re-launched its Facebook page
with a new design and focus on clinical research education as well as
announcing upcoming studies. DCR also joined the Twitter community as
@DCRDenver in 2012, with a focus on its Denver facility and educating
potential participants about the clinical trial process. Dr. Galloway also
joined Twitter as @ChrisGallowayMD this year; his account launched in November
and offers insight to clinical trials as well as general health care news. Dr.
Krishnan continues to share a monthly list of his top clinical reads through a
DaVita blog, featuring thought-provoking articles from clinical journals and
publications as well as respected nephrology blogs.

DaVita, DaVita Clinical Research, DCR and DaVita HealthCare Partners are
trademarks or registered trademarks of DaVita Healthcare Partners Inc. All
other trademarks are the property of their respective owners.

About DaVita

DaVita is the dialysis division of DaVita HealthCare Partners Inc., a Fortune
500® company that, through its operating divisions, provides a variety of
health care services to patient populations throughout the United States and
abroad. A leading provider of kidney care in the United States, DaVita
delivers dialysis services to patients with chronic kidney failure and end
stage renal disease. DaVita strives to improve patients’ quality of life by
innovating clinical care, and by offering integrated treatment plans,
personalized care teams and convenient health-management services. As of
September 30, 2012, DaVita operated or provided administrative services at
1,912 outpatient dialysis centers located in the United States serving
approximately 150,000 patients. The company also operated 24 outpatient
dialysis centers located in five countries outside the United States. DaVita
supports numerous programs dedicated to creating positive, sustainable change
in communities around the world. The company’s leadership development
initiatives and social responsibility efforts have been recognized by Fortune,
Modern Healthcare, Newsweek and WorldBlu. For more information, please visit
DaVita.com.

About DaVita Clinical Research (DCR)

DaVita Clinical Research (DCR), a wholly owned subsidiary of DaVita Healthcare
Partners, Inc., is committed to advancing the knowledge and practice of kidney
care. DCR brings knowledge, skill and expertise to pharmaceutical research,
facilitating the success of its clients’ clinical trials. DCR’s clinical
expertise spans the lifecycle of drug development. DCR’s biorepository, Early
Clinical Research unit (Phase I-IIa) and Clinical Development network of
physicians and investigative sites, data research, Health Economics & Outcomes
Research, Central Laboratory, Advisory Committee prep, and Medical
Communications are focused on providing world-class clinical research in both
complex/specialty populations and therapeutic areas, and especially in CKD and
ESRD populations. To learn more about DCR, visit
www.davitaclinicalresearch.com.

Contact:

DaVita
Bianca Violante, 303-876-6614
Mobile: 443-417-6044
Bianca.Violante@DaVita.com
 
Press spacebar to pause and continue. Press esc to stop.